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A B S T R A C T
Unravelling the origin of genetic alterations from point mutations to chromosomal rearrangements was greatly
enhanced by the discovery of RNA-DNA hybrids (R-loops) that behave as hotspots of genomic instability in a
variety of organisms. Current models suggest that uncontrolled R-loops are a hazard to genome integrity,
therefore, identifying proteins that are involved in recognising and signalling R-loop structures are of key im-
portance. Herein we analysed key RNA-DNA hybrid binding proteins in humans taking advantage of large-scale
gene expression, survival rate, and drug-sensitivity data from cancer genomics databases. We show that ex-
pression of RNA-DNA hybrid binding proteins in various cancer types is associated with survival and may have
contrasting outcomes in responding to therapeutic treatments. Based on the revealed pharmacogenomic land-
scape of human RNA-DNA hybrid binding proteins, we propose that R-loops and R-loop binding proteins are
potentially relevant new epigenetic markers and therapeutic targets in multiple cancers.
1. Introduction
R-loops are special, three-stranded nucleic acid structures, com-
posed of an RNA-DNA hybrid and a non-template, single-stranded DNA.
R-loops have been implicated in a number of human diseases including
repeat-expansion disorders, neurological syndromes, and cancer [1–3].
The molecular symptoms of cancer resemble the genome instability
phenotype of human cell lines that accumulate R-loops and undergo
replication/transcriptional stress-induced DNA damage [4]. Oncogenic
mutation of HRASV12, for instance, has been shown to increase the
protein levels of endogenous RNaseH1 (the enzyme that speciﬁcally
degrades RNA-DNA hybrids) [5], which further supports a mechanistic
link between R-loop formation and tumorigenesis.
It is well-established that single-agent therapy seldom leads to cure
in oncology, therefore identifying novel targets for combination
therapies is necessary [6–8]. Unfortunately, drug-targeting is not fea-
sible in the case of tumour suppressor gene inactivating (loss-of-func-
tion) mutations (constituting most driver mutations in cancer [6],
therefore, ﬁnding alternative targets could help prevent the develop-
ment of drug resistance to targeted therapies. Since R-loops are uni-
versal by-products of transcription [9–11], the R-loop tolerance of
cancer cells could be exploited to sensitize certain tumours to che-
motherapeutic treatments. Reactivating the endogenous response of
cancers to R-loop structures and R-loop-mediated genetic damage (R-
loop intolerance) may make tumours more vulnerable to DNA dama-
ging agents and cell death, which might potentially lead to the devel-
opment of new combination therapies involving cytotoxic regimens and
R-loop-targeting drugs. Various ligands are able target DNA-RNA hy-
brids, including i) small molecule intercalators that directly react with
RNA-DNA hybrids, e.g. ethidium bromide, the aminoglycosides
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neomycin and paramomycin, actinomycin D [12,13], ii) G quadruplex
(G4) ligands since G4s form in a similar genomic context to R-loops
[14,15], e.g. Quarﬂoxin [16] (CX-3543; targeting rDNA G4s; phase II
clinical trial completed for treatment of low grade neuroendocrine
carcinoma - NCT00780663), BSU1051 [15] (targeting human telomeric
G4s), TMPyP4 [17] (targeting G4s in the c-Myc promoter), pyridostatin
[18] (PDS; targeting telomeric G4s and proto-oncogene tyrosine-protein
kinase Src), Braco-19, perylenes and naphthalene diimides, bisquino-
linium derivatives (Phen-DC(3/6) [19], iii) drugs targeting RNA-DNA
hybrid-binding proteins, which have been identiﬁed recently by high-
throughput screening [20,21], e.g. TDRL-505 analogues targeting RPA
[22], or YK-4-279 targeting EWS-FLI1 [23].
There is evidence that R-loops are targetable by anticancer drugs to
revert pathological phenotype [24,25]. For instance, in synovial and
Ewing sarcoma (SS/ES), the use of clinical ATR inhibitors (ATRi) led to
the accumulation of R-loops and increased sensitivity to chemotherapy
[26,27]. PARP inhibitors augmented the antitumor activity of ATRi of
SS cells, suggesting that combination therapies using ATRi are pro-
mising new approaches to treat sarcomas [26]. The anti-tumour drugs
trabectedin and lurbinectedin have been shown to induce replicative
stress and cell death in an R-loop dependent manner [28]. Using a cell
line system where R-loops were stabilized by depleting THOC1 or
BRCA2, cells with increased R-loop levels were more sensitive to tra-
bectedin treatment. Consistently, cancers that accumulate R-loops in
the absence of BRCA1/2 or Fanconi anaemia proteins show higher
sensitivity to trabectedin therapy [29,30].
The EWS-FLI fusion protein has been shown to increase R-loop
formation and inactivates BRCA1 that makes Ewing sarcoma cell lines
hypersensitive to genotoxic drugs such as etoposide, camptothecin, and
PARP inhibitors [31]. Since mutations in EWSR1 and its homologues
are associated with several therapeutically challenging cancers, clas-
togenic agents that augment R-loop mediated stress could be adminis-
tered as potentially eﬀective co-therapeutic treatments in various tu-
mours that are associated with EWSR1 mutations.
Speciﬁc G4 ligands (PDS, Braco-19, and FG) induce R-loop-medi-
ated DNA damage and cell death in human cancer cells [18], estab-
lishing a link between the toxic eﬀects of G4 ligands and R-loop for-
mation. CX-5461 is another G4 ligand showing speciﬁc toxicity against
BRCA-deﬁcient cancer cells and patient-derived xenografts [16]. Repair
of DNA damage induced by CX-5461 required BRCA and NHEJ repair
pathways. CX-5461 is now in an advanced phase I clinical trial for
patients with BRCA1/2 deﬁcient tumours (NCT02719977).
EZM2302 is a selective inhibitor of the histone arginine methylase
CARM1, an enzyme that aﬀects R-loop homeostasis by recruiting
TOP3B to RNA-DNA hybrid structures [32]. EZM2302 exhibits anti-
proliferative eﬀects both in vitro and in vivo [33]. GSK3368715 is a
speciﬁc inhibitor of the PRMT1 histone arginine methyltransferase that
has also been linked to R-loop metabolism [32] and being developed for
the treatment of diﬀuse large B cell lymphoma and solid tumours
(phase I clinical trial; NCT03666988).
Several other compounds have also been described to increase R-
loop levels, including topoisomerase 1 inhibitors [34] (promoting R-
loops by modulating the superhelicity of DNA), spliceosome [35–38]
inhibitors (promoting R-loops through the retention of intronic se-
quences), and reactive aldehydes [39]. Furthermore, the RNA-DNA
degrading enzyme RNase H2 has been recognised as a putative anti-
cancer drug target [40]. With the recently identiﬁed RNase H2 in-
hibitors [41], RNaseH2 might serve as an eﬀective cancer target to
stabilize RNA-DNA hybrids. Finally, a series of anticancer sulphona-
mides have been shown to induce proteasomal degradation of the
U2AF-related splicing factor coactivator of activating protein-1 in
human cancer cell lines [37,42], designating targeted protein de-
gradation by E3 ubiquitin ligases as a potent drug target for selective
inactivation of splicing factors to increase R-loop levels for cancer
therapy.
In the current study we aimed to investigate whether key R-loop-
binding proteins are associated with cancer survival and drug sensi-
tivity. We performed a systematic pharmacogenomic analysis to iden-
tify these associations that may suggest that R-loop formation processes
in cancer cells could be exploited as biomarkers, therapeutic targets, as
well as be used to sensitize certain tumours to chemotherapeutic
treatments. Our results oﬀer new avenues for epigenetic therapies that
are based on modifying R-loop levels in tumours.
2. Materials and methods
2.1. Tumour types included in the analysis
We included in our analysis 33 primary cancer types available from
the Cancer Genome Atlas (TCGA) [43]. These were: Adrenocortical
carcinoma (ACC), Bladder urothelial carcinoma (BLCA), Breast invasive
carcinoma (BRCA), Cervical and endocervical cancers (CESC), Cho-
langiocarcinoma (CHOL), Colon adenocarcinoma (COAD), Lymphoid
Neoplasm Diﬀuse Large B-cell Lymphoma (DLBC), Esophageal
Fig. 1. Median mRNA expression levels of R-loop genes in healthy tissues and in primary tumours, extracted from the Cancer Genome Atlas database. The intensity of
green and red colours is proportional to expression levels.
B. Boros-Oláh, et al. DNA Repair xxx (xxxx) xxxx
2
carcinoma (ESCA), Glioblastoma multiforme (GBM), Head and Neck
squamous cell carcinoma (HNSC), Kidney Chromophobe (KICH),
Kidney renal clear cell carcinoma (KIRC), Kidney renal papillary cell
carcinoma (KIRP), Acute Myeloid Leukaemia (LAML), Brain Lower
Grade Glioma (LGG), Liver hepatocellular carcinoma (LIHC), Lung
adenocarcinoma (LUAD), Lung squamous cell carcinoma (LUSC), Me-
sothelioma (MESO), Ovarian serous cystadenocarcinoma (OV), Pan-
creatic adenocarcinoma (PAAD), Pheochromocytoma and Para-
ganglioma (PCPG), Prostate adenocarcinoma (PRAD), Rectum
adenocarcinoma (READ), Sarcoma (SARC), Skin Cutaneous Melanoma
(SKCM), Stomach adenocarcinoma (STAD), Testicular Germ Cell Tu-
mours (TGCT), Thyroid carcinoma (THCA), Thymoma (THYM), Uterine
Corpus Endometrial Carcinoma (UCEC), Uterine Carcinosarcoma
(UCS), and Uveal Melanoma (UVM).
2.2. Gene expression and survival data analysis
Gene expression data (RNA-sequencing) from the tumour samples
Fig. 2. Association of R-loop gene expression and survival rate in various cancer types. (A) Association heatmap showing the correlation of R-loop gene expression
and overall survival (OS) in TCGA tumours. Statistical signiﬁcance (p < 0.05) is highlighted in green. The number of signiﬁcant associations is 179. (B) Histogram
showing the distribution of survival associations across the studied R-loop genes. The ERBB2 (HER2) oncogene and the TP53 tumour suppressor gene are known
positive controls regarding cancer association (highlighted in blue), having no established R-loop function.
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and overall survival time data were downloaded from TCGA project
[43,44]. Healthy tissue gene expressions were obtained from the web-
site of the Genotype-Tissue Expression (GTEx) project [45]. Survival
analysis was performed and Kaplan-Meier plots were made using the
“survival” package of the R software. The level of signiﬁcance was
p < 0.05. All p-values and adjusted p-values - corrected for multiple
testing using the Benjamini-Hochberg method - are included in Table
S1.
2.3. Cell line analyses
IC50 values of cancer cell lines upon treatment with 276 anticancer
drugs were obtained from the Genomics of Drug Sensitivity in Cancer
(GDSC) database as described and analysed previously [46]. We also
downloaded additional cell line and drug information from the web
page of the GDSC project [47]. Drug sensitivity and gene expression
associations of cancer cell lines were presented as the Spearman cor-
relation of IC50 values and mRNA expression scores of the R-loop genes
analysed. We considered both negative and positive correlations with p-
Fig. 3. Representative survival plots showing the overall survival (OS) of high expressor (red) and low expressor (green) groups in various cancer types. R-loop genes,
cancer IDs, and p-values are indicated. The p-values from Kaplan-Meier analyses of all R-loop genes can be found in Table S1_3.
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values< 0.05. All p-values and adjusted p-values using Benjamini-
Hochberg correction are included in Table S1.
2.4. RNA-DNA hybrid binding proteins
RNA-DNA hybrid binding proteins of various categories having
clear R-loop function were selected for detailed analyses: AQR [48,49],
ATXN1/2 [50–52], BLM [53], BRCA1/2 [54,55], BUB3 [36], BUGZ
(ZNF207) [36], CARM1 [32], DDX19A [56], DHX9 [21,35], EWSR
[31], FANCD2 [57,58], FANCM [58,59], GADD45A [60], PIF1 [61,62],
PRMT1 [32], RNASEH1 [63,64], RNASEH2 [65,66], RTEL1 [17], SETX
[48,67,68], SRSF1 [69], SRSF2 [37], THO/TREX [70], TOP1 [71–74],
TOP3B [32], U2AF1 [37].
3. Results and discussion
To examine the relationship between R-loop genes and cancer, we
ﬁrst determined how many of the recently identiﬁed RNA-DNA hybrid
binding proteins [20] are represented in the registry of cancer genes
[75] representing the largest repository of 2372 genes whose somatic
mutations have cancer driver roles. Of the 448 R-loop genes examined,
92 were cancer genes (Table S1_1) showing statistically signiﬁcant
enrichment (p=0.005792; two prop z test). Next, we selected a core
set of R-loop genes for a detailed analysis of tumorigenesis (n= 36),
representing prominent molecular pathways with clear R-loop asso-
ciation that are also implicated in the formation of cancer (e.g. DNA
topology; RNA-DNA hybrid ribonucleases and helicases; RNA proces-
sing, splicing and export; DNA damage; chromatin modiﬁcations; Table
S1_2). The mRNA expression of these R-loop genes was extracted from
the Cancer Genome Atlas (TCGA) database, allowing us to identify
diﬀerences in the gene expression signatures of healthy tissues and
primary tumours (Fig. 1). For instance, expression of BUB3, DHX9,
PRMT1, THOC4, THOC7, U2AF1 and ZNF207 (BUGZ) was increased in
several primary tumours compared to normal tissues, while SRSF1
(ASF/SF2) was downregulated in most cancers (except for acute mye-
loid leukaemia; LAML). Next, we asked whether R-loop gene expression
levels correlate with survival rate of cancer patients. Taking advantage
of gene expression (RNA-seq) and overall survival (OS) data from the
TCGA, we generated 12,862 Kaplan-Meier survival curves in our ana-
lysis and identiﬁed numerous cases showing signiﬁcant survival asso-
ciation with R-loop gene expression levels (179 at p < 0.05; 33 at
FDR < 0.05; Fig. 2, Supplementary Fig. S1, and Table S1_3). In 70%
of cases (123 at p < 0.05), low expression of R-loop genes was found to
be associated with prolonged survival of cancer patients. Low expres-
sion of RNASEH2A, THOC6, PRMT1, and PIF1, for instance, sig-
niﬁcantly lengthened survival time in mesothelioma (MESO), while low
FANCM mRNA level was advantageous for breast cancer survival
(BRCA; (representative survival plots of low- and high-expressor groups
are shown in Fig. 3). In 30% of cases (52 at p < 0.05), high expression
of R-loop genes was detected and associated with better survival; for
example, TREX1 and BUB3 were beneﬁcial for cervical squamous cell
carcinoma and endocervical adenocarcinoma survival (CESC; Fig. 3 and
Table S1_3). In the case of 10 R-loop genes, long-term survival was
observed exclusively in the low-expressor group of patients, irrespective
of cancer type (ATXN2 (1), BRCA2 (5), CARM1 (6), DDX19A (2),
RNASEH1 (6), THOC2 (4), THOC3 (4), TOP1 (5), U2AF1 (2), ZNF207
(3). For the remaining 26 R-loop genes, high or low expressing groups
varied by cancer type (Supplementary Fig. S2). Most survival asso-
ciations were observed for adrenocortical carcinoma (19 genes) and
mesothelioma (18 genes) (Fig. 2B) correlated with low expression of R-
loop genes (Table S1_3). According to the number of survival asso-
ciations (Fig. 2B), RNASEH2A, BLM, BRCA1, BUB3, and PIF1 appears to
be generally important for survival in multiple cancers, while the eﬀects
of ATXN2, DDX19A and U2AF1 are limited to speciﬁc types of cancer.
To show that our approach can identify real relationships, we in-
cluded an oncogene (ERBB2 - HER2) and a tumour suppressor (TP53) in
our analysis that are known positive controls for cancer association,
with no established R-loop function (Fig. 2, highlighted in blue). R-loop
gene expressions were associated with survival in a similar number of
cancers (or more in a few cases) as ERBB2 and TP53, which demon-
strates the relevance of our observations on RNA-DNA hybrid binding
proteins.
In order to identify R-loop genes that might serve as potential drug
targets for therapeutic intervention, we sought to ﬁnd synergistic in-
teractions between the mRNA expression status of R-loop genes in a
large collection of cancer cell lines and sensitivity to chemotherapeutics
approved by the US Food and Drug Administration (FDA).
Pharmacogenomic (RNA-seq and drug sensitivity) data for 267 antic-
ancer compounds across 1065 cancer cell lines were extracted from the
GDSC database [47], covering a wide range of biological pathways
including protein kinase signalling, cytoskeleton, DNA replication, DNA
repair, and cell cycle control. The total number of signiﬁcant interac-
tions showed considerable variations in the number of drug-speciﬁc
associations (22,414 at p < 0.05; 508 at FDR < 0.05; range: 70–230
interactions per drug; Supplementary Fig. S3 and Table S1_4) and in
the molecular pathways/drug targets involved (Fig. 4). Highly re-
presented pathways included the Ser/Thr protein kinase pathway and
PI3K/RTK/MAPK signalling (Fig. 4, left panel), while the most
common (top10) drug targets were MEK1/2, BRAF, PARP1/2, HSP90,
AKT1/3, GSKs, PI3Ks, IGF1R, ROCK1/3, and EGFR (Fig. 4, right
panel). We found signiﬁcant drug sensitivity associations in 80% of the
studied R-loop genes (29 at p < 0.05; except for BRCA2, BUGZ,
DDX19, RNASEH1, RTEL1, THOC3, and THOC4; Table S1_4), of which
CARM1, EWSR1, DHX9, and THOC1 showed the highest number of
drug interactions (Fig. 5; Table S1_4). This highlights the importance of
considering R-loop gene mRNA expression levels as these may aﬀect
drug response. However, we observed signiﬁcant variability in the
number of drug interactions between various cancer cells lines. For
Fig. 4. Drug sensitivity associations of R-loop
genes grouped by molecular pathways and
drug targets. Left: Distribution of drug inter-
actions over molecular pathways. Green and
red colours indicate higher or lower drug sen-
sitivity, respectively, associated with the
mRNA expression levels of R-loop genes. The
level of signiﬁcance is p < 0.05. The number
of signiﬁcant associations is 22,414. Right:
Statistical representation of drug targets
showing signiﬁcant drug sensitivity interac-
tions with the R-loop genes analysed. Circle
sizes are proportional to drug target fre-
quencies.
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example, lung small cell carcinoma and ovarian cancer cells were
sensitive to most of the compounds tested, but B-cell leukaemia,
Hodgkin's lymphoma, head and neck cancer, and Ewing sarcoma cells
exhibited signiﬁcantly lower drug eﬃcacy (Supplementary Fig. S4,
green bars). These diﬀerences indicate that RNA-DNA hybrid binding
proteins may have contrasting outcomes in responding to various che-
motherapeutic treatments depending on genomic context/cancer type.
For example, in many cancer cell lines, high expression of TREX was
associated with high IC50 values (half maximal inhibitory concentra-
tion) for most drug treatments indicating worse eﬃcacy (i.e. higher
drug concentration achieving half-maximal response) when TREX is
overexpressed. This is entirely consistent with a recent study demon-
strating that reducing the level of TREX1 leads to improved sensitivity
of glioma and melanoma cells to the anticancer drugs topotecan, ni-
mustine, and fotemustine [76]. Chondrosarcoma, lymphoblastic T cell
leukaemia, biliary tract cancer, breast cancer, and pancreatic cancer
cell lines showed exceptionally high IC50 values (resistance) to drug
treatments in the case of increased BUB3 expression. In contrast, sig-
niﬁcant negative correlations were observed between BUB3, EWSR1,
and SETX expression levels and IC50 values in most (but not all) cancer
cell lines, i.e., overexpression of these R-loop genes typically made
cancer cells more sensitive to drug treatment. These results collectively
indicate that targeting TREX, BUB3, SETX, and EWSR to reduce or in-
crease their expression levels in the above tumours may help increase
the eﬃcacy of cancer chemotherapeutics.
Since cancer cell lines - deriving from natural tumours - recapitulate
the genomic context and tissue type of primary cancers [47,77], we
narrowed down the identiﬁed drug interactions to the fraction of R-loop
genes that showed signiﬁcant survival associations in the matching
primary cancer (drug and survival data in non-matching cell types were
Fig. 5. Drug sensitivity associations of R-loop genes in various cancer cell lines. Green and red colours show signiﬁcant negative/positive correlations between the
expression of R-loop genes and drug sensitivities, indicating higher drug sensitivity or resistance of tumour cells against cancer therapeutic drugs. The level of
signiﬁcance is p < 0.05. The number of signiﬁcant associations is 22,414.
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excluded from further analysis; Fig. 6). Collectively, we identiﬁed 1,630
signiﬁcant survival & drug associations (at p < 0.05) related to the
expression of 29 R-loop genes (Table S1_4; seven R-loop genes were
omitted because there was no survival or drug association, or the pri-
mary tumour could not be parsed with the corresponding tumour cell
line). We observed the following trends:
i) most survival interactions (top10) were related to BLM,
RNASEH2A, ATXN1, BRCA1, BUB3, CARM1, GADD45A, FANCD2,
THOC1, and THOC2 associated with various cancers (Fig. 6).
ii) high expression of THOC2 in sarcoma cell lines was associated with
a high IC50 value to CX-5461 (G4 ligand/RNA polymerase I in-
hibitor), suggesting that CX-5461 may be less eﬀective for the
treatment of sarcomas showing high THOC2 expression. On the
other hand, high expression of PIF1, FANCD2 and BRCA1 was as-
sociated with low IC50 (sensitivity) to CX-5461 and low survival in
mesothelioma (Table S1_4). Somewhat diﬀerently, low IC50 to CX-
5461 was associated with high expression of ATXN1 and TREX1
and increased survival in melanoma and endometrial cancer, re-
spectively (Table S1_4).
iii) BRCA1 expression in oesophageal carcinoma cell lines were
associated with high IC50 (resistance) to 5-ﬂuorouracil (5-FU),
while low BRCA1 level was associated with better survival in oe-
sophageal carcinoma. It follows that 5-FU treatment may be eﬃ-
cient for the therapy of BRCA1(-) oesophageal carcinomas.
Similarly, BRCA1 expression in glioma cell lines was associated
with reduced eﬃcacy to (52)-7-oxozeaenol, GDC0941, re-
fametimib, and selumetinib, while low BRCA1 level was beneﬁcial
for the survival of brain lower grade glioma. Moreover, mesothe-
lioma cell lines are resistant to doxorubicin, or OSU-03012 or
thapsigargin when expressing BRCA1. These drugs are potentially
eﬀective chemotherapeutics for BRCA(-) gliomas and mesothe-
liomas. Importantly, 5-FU is being tested in a clinical trial related
to oesophageal carcinoma (NCT00052910), selumetinib is being
investigated in low-grade glioma (NCT01089101), and doxorubicin
is evaluated in patients with mesothelioma (NCT00634205).
iv) Most drug/gene associations were observed for RDEA119, selu-
metinib, and olaparib with most cell lines showing resistance to
RDEA119 and selumetinib, and sensitivity to olaparib associated
showing high R-loop gene expression levels (Supplementary Fig.
S3). For instance, Selumetinib treatment was ineﬀective in stomach
adenocarcinoma cell lines overexpressing AQR (NCT02448290 -
Fig. 6. Survival associations of R-loop genes in primary cancers that show signiﬁcant drug sensitivity associations in the matching cancer cell line. The colour of
survival association map (upper panel) highlights the number of drug interactions. Histogram (lower panel) shows the distribution of survival associations across the
studied R-loop genes with signiﬁcant drug interactions. The level of signiﬁcance is p < 0.05. The number of signiﬁcant associations is 1630.
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Phase 2), in sarcoma cell lines overexpressing ATXN1 or BLM
(NCT03155620 - Phase 2, NCT01752569 - Phase 2), in glioma cell
lines overexpressing BRCA1 or RNASEH2A, in kidney cancer cell
lines overexpressing FANCM or RNASEH2A, and in endometrial
carcinoma cell lines overexpressing TREX1. In terms of patient
survival, low expression of AQR, ATXN1, BLM, BRCA1 and
RNASEH2A was associated with longer survival in the matching
primary cancers, except for FANCM and TREX1 where higher
mRNA level was beneﬁcial for kidney renal clear cell carcinoma
and endometrial carcinoma patients, respectively. Olaparib treat-
ment was eﬀective in prostate adenocarcinoma cells showing high
DDX19A expression, and in the breast cancer cells overexpressing
GADD45A, but mesothelioma cell lines with high ZNF207 (BUGZ)
expression turned out to be resistant to the treatment. Olaparib is in
clinical trial for patients with mesothelioma (NCT03531840 - Phase
2), prostate adenocarcinoma (NCT01682772 - Phase 2) and breast
cancer (NCT02000622 - Phase 3).
v) Several drugs that are now in clinical studies to treat breast cancer
show low IC50 values in breast cancer cell lines with high BRCA1
gene expression. For example, rucaparib (NCT02505048 - Phase 2,
BRCA1,2 mutant patients), dabrafenib (NCT02465060 - Phase 2,
BRAF V600E/R/K/D mutant patients), vismodegib (NCT02465060
- Phase 2 - SMO or PTCH1 mutant patients; NCT02694224 - Phase
2), BMS-754807 (NCT01225172 - Phase 2), and ruxolitimib
(NCT01562873 - Phase 2, NCT02928978 - Phase 2).
vi) Oesophageal carcinoma cell lines with high BRCA1 gene expression
were associated with low IC50 values to motesamib, cisplatin and
trametinib treatments, which are now being tested in various
clinical trials (NCT00101907 - Phase 1, NCT00655876 - Phase 3,
NCT02465060 - Phase 2).
vii) In glioma cell lines, low CARM1 expression was associated with
better eﬃcacy to SN38 treatment (type I topoisomerase inhibitor,
active metabolite of irinotecan), while glioma patients with low
CARM1 levels showed longer survival. It is possible that CARM1(-)
cancers are more susceptible to SN38 drug treatment leading to
inhibition of Top3B and Top1, which could in turn increase R-loop
levels [32] and induce cell death.
The above pharmacogenomic associations of human RNA-DNA hy-
brid binding proteins support the role of R-loop genes in tumorigenesis
and in determining the eﬃciency of tumour therapies. We note that,
however, our analytical approach represents a hypothesis generating
exercise performed on multi-experiment observations to identify all
possible associations of R-loop genes and human malignancies, which
should be experimentally validated in further high-content analysis
projects. Our data suggest that modulating the expression levels of R-
loop genes may aﬀect clinical responses to anticancer drug treatments,
and these expression changes could be used to deﬁne patient groups
who are most likely to beneﬁt from a therapy. Based on the revealed
pharmacogenomic interactions, we propose that R-loops and R-loop
binding proteins are potentially relevant new epigenetic markers and
therapeutic targets in multiple cancers. Further exploration of the re-
cognised associations is expected to improve drug eﬀectiveness and
identify potential combination therapeutics.
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